Heart failure market to grow at 9.6% CAGR in 7MM during 2022-32, forecasts GlobalData

With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a 9.6% compound annual growth rate (CAGR) from $13.5 billion in 2022 to $33.7 billion in 2032 across the seven major markets (7MM*), forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Heart Failure: Seven-Market Drug Forecast and Market Analysis – Update,” reveals that the US will contribute the most to the growth of the HF market due to the higher prevalence of HF, as well as the substantially higher cost of prescription medications compared with Europe and Japan.

Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “The pressure for pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the HF market with the strategies of optimizing treatment safety and compliance, as well as developing novel drug classes. The use of renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose 2 (SGLT2) inhibitors has become well established for HF.”

Over the forecast period, GlobalData expects the launch of promising pipeline drugs Zepbound (tirzepatide), Wegovy (semaglutide), Revascor (rexlemestrocel-L), and Kerendia (finerenone) to increase market size and further promote growth.

Jaddoo concludes: “It will be easier for new drug entrants to capture HF market share if they offer a novel mechanism of action, enhanced clinical profiles, or help to improve compliance.”

*7MM – The US, France, Germany, Italy, Spain, the UK, and Japan.

ENDS

For more information

To gain access to our latest press releases: GlobalData Media Centre

Analysts available for comment. Please contact the GlobalData Press Office:

Email: [email protected]

EMEA & Americas: +44 (0)207 936 6400
Asia-Pacific: +91 40 6616 6809

For expert analysis on developments in your industry, please connect with us on:

GlobalData | LinkedIn | X

Notes to Editors

• Quotes provided by Kajal Jaddoo, Senior Pharma Analyst at GlobalData
• Information is based on GlobalData’s report: Heart Failure: Seven-Market Drug Forecast and Market Analysis – Update
• This press release is written using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts

About GlobalData

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.